Skip to main content

New Device Can Check Markers for Parkinson's, Alzheimer's Disease

Medically reviewed by Carmen Pope, BPharm. Last updated on Nov 17, 2023.

By Dennis Thompson HealthDay Reporter

FRIDAY, Nov. 17, 2023 -- A wireless, noninvasive device has shown promise in detecting the biomarkers of Alzheimer’s and Parkinson’s diseases.

Researchers said the device uses electrical detection to identify proteins associated with Alzheimer’s (amyloid beta and tau) and Parkinson’s (alpha synuclein) in saliva and urine.

“This portable diagnostic system would allow testing at-home and at point of care, like clinics and nursing homes, for neurodegenerative diseases globally,” co-researcher Ratnesh Lal, a professor at the University of California-San Diego Jacobs School of Engineering, said in a university news release.

The device contains a chip with a high-sensitivity transistor that uses DNA to detect amyloid beta, tau or synuclein proteins, researchers said.

Lal said electrical detection is easier to implement and more accurate than chemical detection. He also wanted to create a device that could wirelessly transmit test results to a laptop or smartphone.

Tests on proteins derived from the brains of deceased Alzheimer’s and Parkinson’s patients showed that the biosensors were able to detect specific biomarkers for both conditions with great accuracy, on par with existing methods, findings show.

The device also works well even when samples contain other types of protein, researchers said. Because it works at extremely low concentrations, only small samples are needed, they added.

Tau proteins proved more difficult to detect, but the device can combine results of all three biomarkers to arrive at a reliable overall result, the study found.

UC San Diego has licensed the technology to a biotechnology startup called Ampera Life. Lal is the company’s chairman but does not receive financial support for his research from the company.

Researchers next plan to test blood and cerebro-spinal fluid with the device, before proceeding to saliva and urine samples. The tests would take place in hospital settings and nursing homes.

If those tests go well, Ampera Life plans to seek U.S. Food and Drug Administration approval for the device within the next five to six months. The goal is to have the device on the market in a year.

The findings were published Nov. 13 in the Proceedings of the National Academy of Sciences

Sources

  • University of California-San Diego, news release, Nov. 13, 2023

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2024 HealthDay. All rights reserved.

Posted November 2023

Read this next

Medicare Warnings Stop Nursing Homes From Overusing Antipsychotic Meds

FRIDAY, April 25, 2024 -- Warning letters sent by Medicare officials can prompt a decline in antipsychotic prescriptions for seniors with dementia, a new study finds. Letters...

Healthier Hearts in Middle Age Help Black Women's Brains Stay Strong

FRIDAY, April 26, 2024 -- Better heart health can lead to a sharper mind for middle-aged Black women, a new study says. Black women with worse heart health experienced a 10%...

Genes Could Mix With Pesticide Exposure to Raise Parkinson's Risk

THURSDAY, April 25, 2024 -- It's long been known that exposure to agricultural pesticides can greatly raise a person's odds for Parkinson's disease. New genetics research now...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.